Clinical resistance predictors to first-line VEGFR-TKI monotherapy for metastatic renal cell carcinoma: a retrospective multicenter real-life case series

Abstract

Aim: For many years, systemic treatment of metastatic Renal Cell Carcinoma (mRCC) was based on sequential targeted agent monotherapies. In this real-life case series, we evaluated easily accessible clinical factors useful for disease course prediction.

Methods: We exploited patients' clinical pathological characteristics and systemic treatment outcomes in a real-world population of 365 mRCC patients who received sequential monotherapies in the targeted therapy era, and we identified an early progressors subpopulation, resistant to first-line VEGFR-TKI monotherapy in less than 6 months.

Results: Early progressors (n = 124) show a far worse OS compared with patients progressing beyond the sixth month of therapy (13.5 vs. 44.8 months, P-value < 0.0001, HR = 0.41, 95%CI: 0.29-0.53). However, these patients did not show far worse performance in second and third-line settings compared to first-line responders. In the univariate analysis, IMDC risk class, sarcomatoid features, and Systemic Inflammation Index (SII) were correlated with first-line therapy Progression-Free Survival (PFS1). In multivariate analysis, variables correlated with first-line outcome were IMDC risk class, histotype, and number of metastatic sites at the diagnosis.

Conclusion: Real-world data can contribute to developing easy-to-use prognostic factors associated with refractory disease that could support clinicians in identifying the most appropriate treatment strategy for each patient.

Keywords

Renal cell carcinoma / targeted therapy / tyrosine kinase inhibitor / drug resistance / early progressor / rapidly progressive / prognostic factor / real-world data

References

[1] Institute NC. Cancer Stat Facts: kidney and renal pelvis cancer. National Cancer Institute. Bethesda, MD. Available from: https://seer.cancer.gov/statfacts/html/kidrp.html. [Last accessed on March 22nd 2023]

[2] Osawa T,Kojima T,Eto M.Overview of current and future systemic therapy for metastatic renal cell carcinoma.Jpn J Clin Oncol2019;49:395-403

[3] Moch H,Berney DM.The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours.Eur Urol2022;82:458-68

[4] Heng DY,Regan MM.Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.J Clin Oncol2009;27:5794-9

[5] Heng DY,Regan MM.External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.Lancet Oncol2013;14:141-8 PMCID:PMC4144042

[6] Ko JJ,Kroeger N.The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.Lancet Oncol2015;16:293-300

[7] Kroeger N,Lee JL.Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria.Cancer2013;119:2999-3006 PMCID:PMC3934562

[8] Jin M,Yuan Y.Prognostic and clinicopathological significance of the systemic immune-inflammation index in patients with renal cell carcinoma: a meta-analysis.Front Oncol2021;11:735803 PMCID:PMC8689141

[9] Demasure S,Debruyne PR.Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study.Acta Oncol2022;61:22-9

[10] Porta C.Immune-based combination therapy for metastatic kidney cancer.Nat Rev Nephrol2019;15:324-5

[11] Hu B,Xu Y.Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma.Clin Cancer Res2014;20:6212-22

[12] Escudier B,Schmidinger M.ESMO Guidelines CommitteeRenal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.Ann Oncol2019;30:706-20

[13] Coppin C,Le L,Wilt TJ.Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.BJU Int2011;108:1556-63

[14] Ruiz-Morales JM,Wells JC.First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium.Eur J Cancer2016;65:102-8

[15] Nazha S,Kapoor A.Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting.Curr Oncol2018;25:e576-84 PMCID:PMC6291289

[16] Bekku K,Tsuboi K.Molecular-targeted therapy for metastatic renal cell carcinoma as first-line therapy: a single institution 13-year experience.Acta Med Okayama2022;76:465-72

[17] Porta C,Cartenì G.Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.BJU Int2011;108:E250-7

[18] de Peralta-Venturina M,Amin M.Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases.Am J Surg Pathol2001;25:275-84

[19] Yücel KB,Karakaya S.The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors.Sci Rep2022;12:16559 PMCID:PMC9529965

[20] Motzer RJ,Tomczak P.Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.N Engl J Med2007;356:115-24

[21] Sternberg CN,Mardiak J.Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.J Clin Oncol2010;28:1061-8

[22] Choueiri TK,Sanford BL.Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial.J Clin Oncol2017;35:591-7

[23] Busch J,Weikert S.Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.BMC Cancer2011;11:295 PMCID:PMC3154177

[24] Heng DY,Vaishampayan UN.Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.Ann Oncol2012;23:1549-55 PMCID:PMC3858023

[25] Bersanelli M,Buti S.Metastatic renal cell carcinoma rapidly progressive to sunitinib: what to do next?.Eur Urol Oncol2021;4:274-81.

[26] Choueiri TK,Powles T.METEOR InvestigatorsCabozantinib versus everolimus in advanced renal-cell carcinoma.N Engl J Med2015;373:1814-23

[27] Motzer RJ,McDermott DF.CheckMate 025 InvestigatorsNivolumab versus everolimus in advanced renal-cell carcinoma.N Engl J Med2015;373:1803-13

[28] Vento JA.Treatment of refractory metastatic renal cell carcinoma.Cancers2022;14:5005 PMCID:PMC9599552

[29] Turco F,Di Stefano RF.Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC.Endocr Relat Cancer2021;28:R207-16

[30] Amin MB,Tamboli P.Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases.Am J Surg Pathol2002;26:281-91

[31] Joshi SS,Zibelman M.Treatment facility volume and survival in patients with metastatic renal cell carcinoma: a registry-based analysis.Eur Urol2018;74:387-93 PMCID:PMC7548437

[32] Rizzo M,Pappagallo G.We need both randomized trials and real-world data: the example of everolimus as second-line therapy for mRCC.Future Oncol2014;10:1893-6